Israel Biotech News

Foamix Ltd., a clinical-stage specialty pharmaceutical company has announced that the company has been granted a patent from Indian Patent Office # IN 249626 entitled “Foam Carrier Containing Amphiphilic Copolymeric Gelling Agent.”

BiondVax Announces Receipt of IRB Ethics (“Helsinki”) Committee Approvals for the Initiation of Second Phase II Clinical Trial for Universal Influenza Vaccine. The trial will start in October 2011 with 120 participants over the age of 65.

BiondVax Pharmaceuticals Ltd. is pleased to announce that the company's Chief Scientific Officer, Dr. Tamar Ben-Yedidia, will present the results of the Phase IIa clinical trial on the universal flu vaccine at the 2011 BIO International Convention.

The first-in-class topical Minocycline product, protected by 4 patent applications, is directed for the treatment of Rosacea, Acne, Skin Infections and Chronic Wounds

BiondVax Pharmaceuticals Ltd., an Israeli biopharmaceutical company developing a Universal Influenza Vaccine, today announced that it has raised $1.25 million under its Standby Equity Distribution Agreement (SEDA) with YA Global Investments L.P.

Dr. Tamar Ben-Yedidia will be presenting at the Influenza Congress USA next week in Washington, D.C. BiondVax is currently in Phase IIa clinical trials (human subjects) for its Universal Influenza Vaccine.

Oleaginous Foams – Ideal Vehicles for Lipophilic and Water-Sensitive Drugs, such as Vitamin D, Retinoids and Lipophilic antibiotics

Dr. Tamar Ben-Yedidia will be speaking at the upcoming World Vaccine Congress in Lyon, France on October 4, 2010. She will be updating the congress on the company's progress and upcoming Phase II trials starting in October.

BiondVax Announces Receipt of Ethics (“Helsinki”) Committee Approvals for the Initiation of first Phase II Clinical Trial for Universal Influenza Vaccine

According to Frost & Sullivan, BiondVax is the leading company in the quest for the universal influenza vaccine and has received Frost & Sullivan’s 2010 European Influenza Vaccines Technology Innovation Award.

Chief Scientific Officer, Dr. Tamar Ben Yedidia, will provide an overview of the Company's technology and clinical development progress at two upcoming biopharma industry conferences in Israel and Barcelona, Spain

BiondVax receives funding based on their work on a Universal Flu Vaccine, receiving an additional $1 Million of funding from the Israel Chief Scientist’s office and signing of the final agreement with Yorkville Advisors for $7m

The Patent Covers Foams with Urea, Lactic Acid, Salicylic Acid and Penetration Enhancers

BiondVax Reports Positive Interim Safety Results from Second Phase I/II Universal Influenza Vaccine Trial BiondVax’s Multimeric-001 Universal Flu Vaccine Shown to be Safe and Well Tolerated in trial of 60 elderly participants

BiondVax Pharmaceuticals Ltd. (TASE: BNDK), an Israeli biopharmaceutical company and developer of a Universal Influenza Vaccine, today announced that it has signed a term sheet for a 3 year $7 million standby equity distribution agreement

Micromedic Technologies LTD, the sponsor of Prof. Arber's study demonstrating CD24 as a biomarker for colorectal cancer, is proud to report that the ASCO has selected the study as one of four most important and promising studies for 2009.

The panel members from the Biotech Industry and Biotech HR Companies discussed outcomes of a survey to Biotech / Biopharma CEO as well as current and expected recruitment trends in Biotech and place of new immigrants (Olim) in Life Science Industry.

New CEO Poised to lead Allium to new cycle of growth

Top medical device distributors MenkeMed in Germany and Austria and Ecce Dutoit in the Benelux, signed contract deals to distribute Allium's ureteral and biliary stents

Top Italian medical device distributor NGC Medical signed the contract even before products were awarded CE Mark to ensure exclusivity. Four new products will be exhibited at the EAU 2008 Conference in Milan